Canakinumab is a human monoclonal antibody that targets IL-1β approved for the treatment of CAPS and is undergoing clinical trials for chronic obstructive pulmonary disease (COPD) and gout. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.